|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alkermes Inc., of Cambridge, Mass., and Indianapolis-based Eli Lilly and Co. said results of a Phase II study of inhaled insulin in patients with Type I diabetes demonstrated that the inhaled system achieved blood sugar levels similar to patients treated with injected insulin. Using the standard measure of blood sugar, A1C, patients showed an average level of 7.9 using the Lilly/Alkermes inhaled insulin system, compared to 8 in the injected insulin group. The findings were presented at the American Diabetes Association meeting in San Diego.
o Amarin Corp. plc, of London, said that the Huntington Study Group began recruitment for the U.S. Phase III trial of ...